88 Harcourt Street
ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by co-inventor and co-owner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use.
CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods.
Scientific Advisor and Co-Founder: Dr. Emmanuelle Charpentier
Chairman of the Board and Co-Founder: Shaun Foy
CEO: Eric Rhodes
Please click here for ERS Genomics' technology.